what is glp-1 friendly Crafting product claims in the weight-loss drug era Caution advised for GLP-1 labeling

The expiry of semaglutide patents in India and Canada (January 2026) and Brazil (March 2026) opens the doors for affordable alternatives to penetrate emerging markets, where obesity and diabetes are growing public health challenges

Concurrent federal action will provide the most robust protection against all the illegal and deceptive conduct. The statements issued by medical societies and government officials are important not just for health care professionals, but also for educating patients about how obesity management should be approached, according to Sangeeta Kashyap, MD, assistant chief of clinical affairs in the department of endocrinology, diabetes and metabolism at NewYork-Presbyterian/Weill Cornell Medical Center and a Healio | Endocrine Today Co-editor

So scientifically, that has not been proven, even though there are warnings in the product monographs, said Goldenberg

& Freissmuth, M

A., Castillo, M., Rodrigo, J